share_log

Resonate Blends Executes a Share Exchange Agreement With Emergent Health Corp.

Resonate Blends Executes a Share Exchange Agreement With Emergent Health Corp.

Resonate Blends 與 Emergent Health Corp. 簽署股票交換協議
Accesswire ·  03/15 23:20

NORTH BERGEN, NJ / ACCESSWIRE / March 15, 2024 / Resonate Blends, Inc. (OTCQB:KOAN) ("Resonate Blends" or the "Company") is pleased to report it has completed a Share Exchange Agreement with the holders of certain preferred stock of Emergent Health Corp. (OTC Pink:EMGE) ("Emergent Health" or "EMGE") (The "Agreement"), with the closing having taken place on March 14, 2024. Resonate Blends, the parent company, will become known as Apollo Biowellness, Inc. ("Apollo Biowellness"). The company is now located at One Marine Plaza, Suite 305A, North Bergen, NJ 04047.

新澤西州北卑爾根/ACCESSWIRE/2024年3月15日/Resonate Blends, Inc.(OTCQB: KOAN)(“Resonate Blends” 或 “公司”)欣然報告說,它已與Emergent Health Corp.(場外交易鏈接:EMGE)(“Emergent Health” 或 “EMGE”)的某些優先股(“協議”)的持有人完成了股票交換協議,收盤時已結束於 2024 年 3 月 14 日舉行。母公司Resonate Blends將更名爲阿波羅生物健康有限公司(“阿波羅生物健康”)。該公司現在位於新澤西州北卑爾根海洋廣場一號305A套房 04047。

The Company (to be known as Apollo Biowellness) is a holding company focused on regenerative medicine sold primarily to doctor's offices and clinics, as well as the public. The Company now consists of the following subsidiaries: Evolutionary Biologics, Integrative Practice Solutions LLC and Juventix Regenerative Medical LLC, and soon-to-be-launched Maximus Mean's Health.

該公司(更名爲Apollo Biowellness)是一家控股公司,專注於再生醫學,主要銷售給醫生辦公室和診所以及公衆。該公司現在由以下子公司組成:Evolutionary Biologics、Integrative Practice Solutions LLC和Juventix Regenerative Medical LLC以及即將成立的Maximus Mean's Health。

The Company, as Apollo Biowellness, is a synergistic ecosystem of companies disrupting the next generation of the $5.6 trillion Global Health & Wellness Market. The global regenerative medicine market is currently at $20.04 billion in 2021 and predicted to be worth around $125.54 billion by 2030. We offer a one-stop solution for regenerative medicine with superior proprietary products and processes focused on the $1.1 trillion Personal Care, Beauty and Anti-Aging markets, with products sold through professional offices and directly to consumers. Our offerings include skin care, wound care, cosmetics, regenerative aesthetics, hair growth, ED, longevity/anti-aging, osteoarthritis and more. We foresee significant growth once we open DTC and OTC markets with FDA approval, which we will apply for, for skin care and hair growth products using human exosomes. We currently have a professional sales force with 700+ independent sales reps and distribution partners covering all aspects of our brand ecosystem. The company's subsidiaries will benefit from synergies in all backroom disciplines as well as sales & marketing and a seasoned collaborative management team.

該公司名爲Apollo Biowellness,是一個由公司組成的協同生態系統,正在顛覆下一代5.6萬億美元的全球健康與保健市場。2021年,全球再生醫學市場目前爲200.4億美元,預計到2030年將達到約1255.4億美元。我們爲再生醫學提供一站式解決方案,提供卓越的專有產品和工藝,專注於1.1萬億美元的個人護理、美容和抗衰老市場,產品通過專業辦公室直接銷售給消費者。我們的產品包括皮膚護理、傷口護理、化妝品、再生美學、頭髮生長、ED、長壽/抗衰老、骨關節炎等。我們預計,一旦我們在獲得美國食品藥品管理局批准的情況下開放DTC和OTC市場,使用人類外泌體的護膚和頭髮生長產品將獲得美國食品藥品管理局的批准,我們將申請該批准。我們目前擁有一支專業的銷售隊伍,擁有700多名獨立銷售代表和分銷合作伙伴,涵蓋我們品牌生態系統的各個方面。該公司的子公司將受益於所有幕後領域以及銷售和營銷以及經驗豐富的協作管理團隊的協同效應。

Emergent Health Corp. will continue with the operations of Wholistic Brands, a majority-controlled subsidiary as a separate, but affiliated entity of the Parent Company, it is a brand that represents the best natural formulas made from plant-based ingredients, including shelf-stable plant-based exosomes. Wholistic is developing products in support of our suite of businesses while building a proprietary D2C and consumer business around clean wholistic health.

Emergent Health Corp. 將繼續經營Wholistic Brands的運營。Wholistic Brands是母公司控股的子公司,是母公司的一個獨立但附屬的實體,該品牌代表了由植物性成分製成的最佳天然配方,包括可保質期的植物性外泌體。Wholistic正在開發支持我們的業務套件的產品,同時圍繞清潔整體健康建立專有的D2C和消費者業務。

As part of the Agreement, Jim Morrison is the new Chairman of the Board of Directors and President/CEO of the Company. Morrison has stepped down as CEO/President of Emergent Health Corp. but will continue as Chairman of the Board of Directors of Emergent. The new management of Emergent will also be appointed and will report to the Board of the Company.

作爲協議的一部分,吉姆·莫里森是公司新任董事會主席兼總裁/首席執行官。莫里森已辭去Emergent Health Corp首席執行官/總裁的職務,但將繼續擔任Emergent董事會主席。還將任命Emergent的新管理層,並將向公司董事會報告。

Jim Morrison is considered by many to be one of the leading personal care strategists in the world, as well as one of the top executives. Morrison was Chairman and President/CEO of Emergent Health Corp., a dynamic company in the wellness and regenerative biologics space. He has most recently been CEO of StarShop, which was the first celebrity-driven video shopping app, that was launched in partnership with SPRINT. His track record of leadership and accomplishment in the personal care products space has been unparalleled. Morrison was President of L'Oreal for over nine years. He was responsible for many acquisitions, including both Redken and Matrix, and top-line growth that averaged over 20% during his tenure. Prior to L'Oreal, Morrison was President and CEO of Graham Webb, one of the most successful startups in the hair care space. After leaving L'Oreal Morrison was CEO and owner of Sexy Hair Concepts for four years. In 2006, Business Week Magazine wrote, "Over the last two decades, Mr. Morrison has had a profound impact on the American Beauty Industry. In the industry's history no other executive has had the level of financial responsibility or breadth of organizational experience as Jim. His devotion to, and success within the industry is unmatched."

許多人認爲吉姆·莫里森是全球領先的個人護理策略師之一,也是高層管理人員之一。莫里森曾是Emergent Health Corp. 的董事長兼總裁兼首席執行官,該公司是一家在健康和再生生物製劑領域充滿活力的公司。他最近擔任StarShop的首席執行官,這是第一款由名人驅動的視頻購物應用程序,是與SPRINT合作推出的。他在個人護理產品領域的領導和成就記錄是無與倫比的。莫里森擔任歐萊雅總裁超過九年。他負責許多收購,包括Redken和Matrix,以及在他任職期間平均超過20%的收入增長。在加入歐萊雅之前,莫里森曾擔任格雷厄姆·韋伯的總裁兼首席執行官,格雷厄姆·韋伯是護髮領域最成功的初創公司之一。離開歐萊雅後,莫里森曾擔任Sexy Hair Concepts的首席執行官兼所有者四年。2006年,《商業週刊》雜誌寫道:“在過去的二十年中,莫里森先生對美國美容行業產生了深遠的影響。在該行業的歷史上,沒有其他高管像吉姆那樣具有財務責任水平或豐富的組織經驗。他對該行業的熱愛和成功是無與倫比的。”

As part of the transaction, the Company is conveying the previous assets of Resonate Blends to prior management.

作爲交易的一部分,公司正在將Resonate Blends先前的資產移交給前任管理層。

About the former parent company Resonate Blends, Inc. (OTCQB:KOAN)

關於前母公司 Resonate Blends, Inc.(OTCQB: KOAN)

Resonate Blends is the former parent company, and as part of the transaction all the Intellectual Property and assets associated with it are being conveyed and transferred back to the former founding executive of Resonate Blends.

Resonate Blends是前母公司,作爲交易的一部分,所有與之相關的知識產權和資產都將移交給Resonate Blends的前創始高管。

Apollo Biowellness is the new parent company and has no connection with the previous business of Resonate Blends.

Apollo Biowellness是新的母公司,與Resonate Blends之前的業務沒有任何關係。

ABOUT EMERGENT HEALTH CORP./Apollo Biowellness, Inc. (OTCMarkets Pink EMGE)

關於緊急健康公司/Apollo Biowellness, Inc.(場外市場粉紅EMGE)

Emergent Health curates, develops and sells products in the regenerative health space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through "Content Based Shopping" using "Influencers" to successfully position products throughout the United States and Internationally. Evolutionary Biologics is a new kind of biologics company founded for a clear purpose: bring cutting-edge regenerative products to the medical community. Emergent asserts that its products are not approved by the FDA to diagnose, treat, cure or prevent any disease(s). For more information, please visit Emergent's website.

Emergent Health 策劃、開發和銷售再生健康領域的產品。其產品包括可攝入物和外用藥物,適合全家使用。該公司使用 “Influencers” 在線分銷其產品,並通過 “基於內容的購物” 成功地在美國和國際上定位產品。Evolutionary Biologics是一家新型的生物製劑公司,其成立的目的很明確:爲醫學界帶來尖端的再生產品。Emergent斷言,其產品未經美國食品藥品管理局批准用於診斷、治療、治癒或預防任何疾病。欲了解更多信息,請訪問Emergent的網站。

Before using any of our products, you should always consult with your veterinarian and/or family doctor.

在使用我們的任何產品之前,您應始終諮詢您的獸醫和/或家庭醫生。

Forward-Looking Statements

前瞻性陳述

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

本新聞稿可能包含1933年《證券法》第27A條和1934年《證券交易法》第21E條所指的 “前瞻性陳述”。此類陳述包括但不限於與我們的產品開發計劃有關的任何陳述以及任何其他非歷史事實的陳述。此類陳述涉及風險和不確定性,可能會對我們的業務、經營業績、財務狀況和股價產生負面影響。可能導致實際結果與管理層當前預期存在重大差異的因素包括與我們的籌資能力、監管批准程序、候選藥物的開發、測試、生產和銷售、專利和知識產權問題以及戰略協議和關係相關的風險和不確定性。除非法律要求,否則我們明確表示不承擔任何義務或承諾公開發布此處包含的任何前瞻性陳述的任何更新或修訂,以反映我們預期的任何變化或任何此類陳述所依據的事件、條件或情況的任何變化。公司向美國證券交易委員會提交的最新10-K表年度報告中的 “風險因素” 中包含了對可能影響公司業務(包括其任何子公司業務)的風險和不確定性的完整討論。

Corporate Contact:

公司聯繫人:

Jim Morrison
CEO/Director
jmorrison@evolutionarybiologics.com
203-253-9191

吉姆·莫里森
首席執行官/總監
jmorrison@evolutionarybiologics.com
203-253-9191

Contact Information:

聯繫信息:

Jim Morrison
President/CEO
jmorrison@evolutionarybiologics.com
2032539191

吉姆·莫里森
總裁/首席執行官
jmorrison@evolutionarybiologics.com
2032539191

Jim Zimbler
President, Emergent Health
jzimbler@emergenthealthcompany.com
6318061420

吉姆·齊姆布勒
緊急健康總裁
jzimbler@emergenthealthcompany.com
6318061420

SOURCE: Resonate Blends, Inc.

來源:Resonate Blends, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論